

## **Patent Updates**

Suven Life Sciences secures Product Patents in Brazil, Eurasia, Hong Kong, Israel, Japan, Macau, South Africa and USA

HYDERABAD, INDIA (January 27, 2025) – Suven Life Sciences Ltd secures one (1) product patent from Brazil (BR112019003932-5), one (1) product patent from Eurasia (047954), two (2) product patents from Hong Kong (HK40071167) (HK40071665), one (1) product patent from Israel (279045), one (1) product patent from Japan (7556031), one (1) product patent from Macau (J/008390), one (1) product patent from South Africa (2022/05914) and one (1) product patent from USA (12122779) corresponding to the new Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2037, 2039, 2040, 2040, 2040, 2040, 2040, 2039 and 2039 respectively.

The granted claims of the patents include the class of selective Histamine H3, 5HT6 and M1 PAM compounds and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Excessive Daytime Sleepiness in Narcolepsy Huntington's disease, Parkinson and Schizophrenia etc.

## **Disclaimer and Risk Statement:**

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time